JPWO2019213434A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019213434A5 JPWO2019213434A5 JP2020561076A JP2020561076A JPWO2019213434A5 JP WO2019213434 A5 JPWO2019213434 A5 JP WO2019213434A5 JP 2020561076 A JP2020561076 A JP 2020561076A JP 2020561076 A JP2020561076 A JP 2020561076A JP WO2019213434 A5 JPWO2019213434 A5 JP WO2019213434A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- type lectin
- caar
- seq
- cysteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003930 C-Type Lectins Human genes 0.000 claims description 61
- 108090000342 C-Type Lectins Proteins 0.000 claims description 61
- 108091033319 polynucleotide Proteins 0.000 claims description 54
- 102000040430 polynucleotide Human genes 0.000 claims description 54
- 239000002157 polynucleotide Substances 0.000 claims description 54
- 235000018417 cysteine Nutrition 0.000 claims description 26
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 26
- 108010043610 KIR Receptors Proteins 0.000 claims description 24
- 102000002698 KIR Receptors Human genes 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 23
- 102000016359 Fibronectins Human genes 0.000 claims description 20
- 108010067306 Fibronectins Proteins 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 19
- 230000003834 intracellular effect Effects 0.000 claims description 18
- 230000011664 signaling Effects 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 11
- 208000017169 kidney disease Diseases 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 230000001086 cytosolic effect Effects 0.000 claims description 7
- 230000019491 signal transduction Effects 0.000 claims description 6
- 230000001434 glomerular Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 101000945339 Homo sapiens Killer cell immunoglobulin-like receptor 2DS2 Proteins 0.000 claims description 3
- 102100033630 Killer cell immunoglobulin-like receptor 2DS2 Human genes 0.000 claims description 3
- 208000022461 Glomerular disease Diseases 0.000 claims description 2
- 208000033709 Primary membranous glomerulonephritis Diseases 0.000 claims description 2
- 230000000139 costimulatory effect Effects 0.000 claims description 2
- 231100000852 glomerular disease Toxicity 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102100029392 Secretory phospholipase A2 receptor Human genes 0.000 claims 9
- 101710122046 Secretory phospholipase A2 receptor Proteins 0.000 claims 9
- 150000001413 amino acids Chemical group 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 22
- 150000007523 nucleic acids Chemical group 0.000 description 22
- 238000000034 method Methods 0.000 description 17
- 125000003275 alpha amino acid group Chemical group 0.000 description 15
- 102000004856 Lectins Human genes 0.000 description 6
- 108090001090 Lectins Proteins 0.000 description 6
- 239000002523 lectin Substances 0.000 description 6
- 108010039491 Ricin Proteins 0.000 description 4
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 3
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024027975A JP2024059867A (ja) | 2018-05-02 | 2024-02-28 | ホスホリパーゼａ２受容体キメラ自己受容体ｔ細胞の組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862665863P | 2018-05-02 | 2018-05-02 | |
| US62/665,863 | 2018-05-02 | ||
| PCT/US2019/030459 WO2019213434A1 (en) | 2018-05-02 | 2019-05-02 | Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024027975A Division JP2024059867A (ja) | 2018-05-02 | 2024-02-28 | ホスホリパーゼａ２受容体キメラ自己受容体ｔ細胞の組成物および方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021522790A JP2021522790A (ja) | 2021-09-02 |
| JPWO2019213434A5 true JPWO2019213434A5 (https=) | 2022-05-13 |
| JP2021522790A5 JP2021522790A5 (https=) | 2022-05-13 |
| JP7519906B2 JP7519906B2 (ja) | 2024-07-22 |
Family
ID=68386834
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561076A Active JP7519906B2 (ja) | 2018-05-02 | 2019-05-02 | ホスホリパーゼａ２受容体キメラ自己受容体ｔ細胞の組成物および方法 |
| JP2024027975A Pending JP2024059867A (ja) | 2018-05-02 | 2024-02-28 | ホスホリパーゼａ２受容体キメラ自己受容体ｔ細胞の組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024027975A Pending JP2024059867A (ja) | 2018-05-02 | 2024-02-28 | ホスホリパーゼａ２受容体キメラ自己受容体ｔ細胞の組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20210095001A1 (https=) |
| EP (1) | EP3813885A4 (https=) |
| JP (2) | JP7519906B2 (https=) |
| KR (1) | KR20210007998A (https=) |
| CN (1) | CN112312930A (https=) |
| AU (1) | AU2019262131A1 (https=) |
| CA (1) | CA3098865A1 (https=) |
| MX (1) | MX2020011610A (https=) |
| WO (1) | WO2019213434A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CN113527507A (zh) * | 2020-04-16 | 2021-10-22 | 上海赛比曼生物科技有限公司 | 靶向cd22的嵌合抗原受体及其制法和应用 |
| CA3197423A1 (en) | 2020-11-04 | 2022-05-12 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| WO2022136503A1 (en) | 2020-12-22 | 2022-06-30 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) | Chimeric autoantibody receptor (caar) comprising a nicotinic acetylcholine receptor autoantigen |
| EP4308133A4 (en) | 2021-03-17 | 2025-01-22 | Myeloid Therapeutics, Inc. | MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| EP4083061A1 (en) * | 2021-04-30 | 2022-11-02 | Kilometro Rosso SPA | Fusion proteins and use thereof in the treatment of membranous nephropathy |
| AU2022272235A1 (en) | 2021-05-11 | 2023-12-21 | Create Medicines, Inc. | Methods and compositions for genomic integration |
| EP4380963A4 (en) * | 2021-08-05 | 2025-06-04 | The Trustees of The University of Pennsylvania | Compositions and methods of chimeric autoantibody receptor cells expressing extended phospholipase a2 receptor fragments |
| US20250049849A1 (en) * | 2021-12-15 | 2025-02-13 | Shanghai Synvida Biotechnology Co. Ltd. | Product and method for treating thrombocytopenia |
| CN114588881B (zh) * | 2022-03-07 | 2023-07-18 | 大连理工大学 | 免疫吸附剂及其制备方法 |
| CN116082517B (zh) * | 2022-05-26 | 2025-08-22 | 成都地奥制药集团有限公司 | 融合蛋白及其用途 |
| IL317811A (en) | 2022-07-25 | 2025-02-01 | Interius Biotherapeutics Inc | Mutated polypeptides, compositions containing them and uses thereof |
| CN115838751A (zh) * | 2022-11-22 | 2023-03-24 | 迪亚莱博（张家港）生物科技有限公司 | 一种磷脂酶a2受体重组蛋白的制备方法 |
| AU2024318666A1 (en) * | 2023-08-01 | 2026-01-22 | Merida Biosciences, Inc. | Molecules for controlling autoimmune response |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| ZA973051B (en) | 1996-04-24 | 1998-10-12 | Genentech Inc | Type c lectins |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| EP2318036B1 (en) * | 2008-06-30 | 2015-06-03 | The Regents of the University of Michigan | Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013007640A1 (en) * | 2011-07-08 | 2013-01-17 | Centre Leon Berard | Pla2r1 as anti-tumoral compound and as biomarker for the detection of cancer |
| US9708384B2 (en) * | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
| AU2013243948A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| DK3166968T3 (da) * | 2014-05-02 | 2021-12-06 | Univ Pennsylvania | Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler |
| KR20180072662A (ko) | 2015-07-10 | 2018-06-29 | 추 드 니스 | Pla2r1 에피토프 프로파일 및 확산의 분석을 기반으로 한 막성 신병증의 예후 및 모니터링 |
| WO2018031947A1 (en) | 2016-08-12 | 2018-02-15 | Immunowork, Llc | Diagnosis, prevention, and/or treatment of autoimmune diseases |
| WO2018127585A1 (en) | 2017-01-06 | 2018-07-12 | Txcell | Monospecific regulatory t cell population with cytotoxicity for b cells |
| CN107663235B (zh) * | 2017-08-11 | 2018-05-22 | 南京诺唯赞医疗科技有限公司 | 特发性膜性肾病相关的pla2r重组蛋白及其应用 |
-
2019
- 2019-05-02 CA CA3098865A patent/CA3098865A1/en active Pending
- 2019-05-02 US US17/051,248 patent/US20210095001A1/en not_active Abandoned
- 2019-05-02 AU AU2019262131A patent/AU2019262131A1/en not_active Abandoned
- 2019-05-02 KR KR1020207033822A patent/KR20210007998A/ko not_active Ceased
- 2019-05-02 CN CN201980042269.7A patent/CN112312930A/zh active Pending
- 2019-05-02 EP EP19796773.0A patent/EP3813885A4/en active Pending
- 2019-05-02 MX MX2020011610A patent/MX2020011610A/es unknown
- 2019-05-02 WO PCT/US2019/030459 patent/WO2019213434A1/en not_active Ceased
- 2019-05-02 JP JP2020561076A patent/JP7519906B2/ja active Active
-
2021
- 2021-12-06 US US17/543,429 patent/US11884716B2/en active Active
-
2024
- 2024-02-28 JP JP2024027975A patent/JP2024059867A/ja active Pending
- 2024-04-19 US US18/640,092 patent/US20240383965A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522790A5 (https=) | ||
| JP2021526795A5 (https=) | ||
| JP6923714B2 (ja) | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 | |
| US20240158507A1 (en) | VISTA Antagonist and Methods of Use | |
| JPWO2019213434A5 (https=) | ||
| JP4448282B2 (ja) | ヒト癌を処置するのに有用なキメライムノレセプター | |
| Blazar et al. | Recent advances in graft‐versus‐host disease (GVHD) prevention | |
| JP6783797B2 (ja) | 抗がん融合ポリペプチド | |
| AU2015274504B2 (en) | Use of VISTA agonists and antagonists to suppress or enhance humoral immunity | |
| KR102235202B1 (ko) | T 세포 수용체 베타 불변 영역에 대한 항원 결합 도메인을 갖는 키메라 항원 수용체(car) | |
| JP2022542543A (ja) | 抗ｄｌｌ３キメラ抗原受容体及びその使用 | |
| UA125207C2 (uk) | Комбінована терапія для лікування злоякісної пухлини | |
| AU2024201301A1 (en) | Variant ICOS Ligand immunomodulatory proteins and related compositions and methods | |
| JP2021511826A5 (https=) | ||
| CN112424230A (zh) | 双功能结合多肽 | |
| JP2012531400A (ja) | 少なくとも２つのα３ドメインを含むＨＬＡ−Ｇの多量体ポリペプチド及び医薬としてのその使用 | |
| JP2019513394A5 (https=) | ||
| JP2021512615A5 (https=) | ||
| JP2009515555A (ja) | ヒト癌の治療に有用なキメラ免疫受容体 | |
| CN107835820A (zh) | 识别癌症特异性IL13Rα2的CAR T细胞 | |
| KR20160058767A (ko) | Ｔ 세포 수용체 | |
| CN110114371A (zh) | 嵌合抗原受体 | |
| CN115038719B (zh) | 与cd300c抗原或其受体特异性结合的嵌合抗原受体 | |
| JP2019530441A5 (https=) | ||
| JPWO2019144095A5 (https=) |